Increased investment spurs advances in gene therapy
The success of approved products for rare illnesses has opened the door for gene-based treatments of more prevalent diseases, finds Frost & Sullivan.
Currently, gene therapy is recovering across the biopharmaceutical industry as the quality and effectiveness of the technology shows gradual, but marked improvement. While safety concerns during the nascent phases affected technology adoption, novel delivery vector systems have facilitated the development of numerous safe therapeutic solutions and have given the technology a second wind.
Analysis from Frost & Sullivan, Advances in Gene Therapy, finds gene therapy can be effective for several emerging disease groups, including ocular diseases, diabetes, infectious illnesses and many of cancer types. Gene therapy for rare genetic diseases has been the most fruitful in terms of clinical trials. The success of these niche therapeutics has paved the way for similar applications for additional widespread diseases.
Until now, adverse side effects, as well as high costs, had made regulatory bodies and patients skeptical about gene therapy, while health insurance companies had been reluctant to provide reimbursements.
However, an increasing number of collaborations among research and pharmaceutical companies to understand the potential applicability of gene therapy for prevalent diseases, such as cancer, will help develop novel and approved modes of treatment.
"With the rise in clinically proven remedies, it is likely insurance companies will begin to acknowledge the commercial advantage of gene therapy," said TechVision Senior Research Analyst Madhumitha Rangesa.
Improvements in vector technology and delivery systems will further enhance efficacy and clinical outcomes. Currently, the ocular diseases space is witnessing a rapid influx of companies equipped with the appropriate vector delivery systems capable of carrying small gene loads to specific target sites in the human body.
The use of combination therapies is another novel idea that will boost the therapeutic effects of gene technology. Competing industries, like cancer immunotherapy, are already shifting towards combination therapies within their own industry, with conventional or other burgeoning therapeutic fields.
Once the gene therapy industry bounces back with noteworthy products, governments around the world will step in to accelerate innovation. In the U.S., the growing emphasis on precision medicine capable of catering to a specific subset of people based closely on their genetic makeup is widening the scope for gene-based therapeutics.
"North America has the highest number of clinical trials in gene therapy largely due to the extensive focus on innovation and availability of funding," noted Rangesa. "In terms of market commercialization, Europe has overtaken North America with two products approved for commercialization within Europe and one approved for commercialization globally; however Asia is slowing catching up."
The global interest in the technology will attract investments and support the evolution of gene-based remedies from production and clinical trials to commercialization.
News 3 ways ChatGPT will impact pharma marketing teamsWhat does the rise of AI-powered chatbots such as ChatGPT and GPT-4 mean for pharma marketeers?
News Eli Lilly, Novo Nordisk, and Sanofi cut insulin prices by up to 78%Insulin prices have dropped in a stark play by the three biggest makers of the product, after calls from the top of the US government.
News Pharma Supply Chain People MovesThe latest appointments and promotions across the pharmaceutical supply chain.
News Open letter challenges EU Commission on medicine supply chainIn an open letter to the European Commission, Medicines for Europe calls for a new medicine security contract with their goal to improve access to medicine and ensure a secure supply chain to Europe.
News The Biggest Drug Approvals of 2022A carefully curated list of the most notable drug approvals of the past year, covering neurology, oncology, and COVID-19, as well as a look at the most promising drugs up for review in 2023.
News Eli Lilly gets ready to launch five new drugs in 2023Eli Lilly, the American pharmaceutical company (IN, USA) are gearing up for a big year ahead, with hopes to launch five new drugs and capitalise on growing obesity and Alzheimer’s disease markets.
News Amgen buys Horizon for $27.8 billion in bold step into the rare disease marketAmgen Inc buys pharmaceutical company Horizon Therapeutics in a multibillion-dollar deal, in hopes to capitalise on it's portfolio of drugs in the highly sort after rare disease market.
News Merck to donate new Ebola vaccine to defend against outbreaks in UgandaPharmaceutical giant Merck has announced they will be speeding up the processing of a new vaccine against the latest strain of the Ebola virus, to be donated to a global non-profit organisation for distribution
Position your company at the heart of the global Pharma industry with a CPHI Online membership
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
Generate high-quality, engaged leads for your business, all year round
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
Your company’s profile boosted at all participating CPHI events
An easy-to-use platform with a detailed dashboard showing your leads and performance